---
layout: default
title: Diclofenac Sodium
parent: 僅模型預測 (L5)
nav_order: 182
evidence_level: L5
indication_count: 0
---

# Diclofenac Sodium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Diclofenac Sodium: Drug Repurposing Evaluation — Awaiting TxGNN Prediction

## One-Sentence Summary

Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID), commonly prescribed for pain and inflammatory conditions. The TxGNN model has **not yet generated predicted new indications** for this drug. The evidence pack currently contains significant data gaps that must be resolved before a repurposing analysis can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Pain and inflammatory conditions (NSAID — details pending from licence data) |
| Predicted New Indication | — None (TxGNN prediction not yet available) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No prediction or supporting studies available |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 68 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, no TxGNN prediction has been generated for Diclofenac Sodium, so a mechanistic plausibility assessment cannot be performed at this stage.

Diclofenac sodium is a well-established NSAID that works primarily by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This mechanism underlies its anti-inflammatory, analgesic, and antipyretic effects. It is one of the most widely prescribed NSAIDs globally, with 68 registered products in the Malaysian market, reflecting its broad clinical utility across multiple dosage forms and indications.

Once the TxGNN model generates candidate indications, the COX-inhibition mechanism — along with emerging evidence for anti-inflammatory pathways in conditions such as neurodegeneration, certain cancers, and cardiovascular remodelling — could provide a plausible biological rationale for repurposing. However, this analysis is contingent on completing the data gaps identified below.

---

## Clinical Trial Evidence

Currently no predicted indication is available; therefore, no targeted clinical trial search has been performed.

---

## Literature Evidence

Currently no predicted indication is available; therefore, no targeted literature search has been performed.

---

## Malaysia Market Information

68 registered products were identified via the NPRA database query (2026-03-27). However, detailed licence-level information (authorisation numbers, product names, dosage forms, and approved indication text) was **not populated** in the evidence pack.

> **Action Required:** Re-query the NPRA database to retrieve full licence details for all 68 registrations and populate the `licenses` array.

---

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug–drug interaction data were not available in the current evidence pack.

**Known general NSAID class concerns** (for reference only — not sourced from this evidence pack):
- Gastrointestinal bleeding and ulceration risk
- Cardiovascular thrombotic events (especially with prolonged use)
- Renal impairment
- Hypersensitivity reactions (including aspirin-sensitive asthma)

---

## Data Gaps Requiring Resolution

The following blocking and high-severity gaps were identified:

| ID | Category | Item | Severity | Impact | Remediation |
|----|----------|------|----------|--------|-------------|
| DG001 | Drug Level | TFDA Package Insert Warnings / Contraindications | **Blocking** | Cannot enter S1 safety preliminary assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Affects mechanistic relevance analysis | Query DrugBank API (DrugBank ID not yet mapped) |
| — | Drug Level | DrugBank ID | High | Required for MOA, DDI, and toxicity data retrieval | Map "DICLOFENAC SODIUM" → DrugBank (likely **DB00586**) |
| — | Drug Level | Licence details (68 records) | Medium | Cannot display approved indications or dosage forms | Re-query NPRA with full field extraction |
| — | Prediction | TxGNN predicted indications | **Blocking** | No repurposing candidates to evaluate | Run TxGNN KG + DL prediction pipeline |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack is substantially incomplete — no TxGNN prediction has been generated, the DrugBank ID is unmapped, and all safety fields remain empty. A meaningful repurposing evaluation cannot be conducted until these foundational data gaps are resolved.

**To proceed, the following is needed:**
1. **Map DrugBank ID** — Diclofenac sodium is expected to correspond to **DB00586**; confirm and populate `drugbank_id`
2. **Run TxGNN prediction pipeline** — Execute both KG and DL prediction methods to generate candidate indications
3. **Retrieve NPRA licence details** — Re-query to populate authorisation numbers, product names, dosage forms, and approved indication text for the 68 registrations
4. **Obtain package insert data** — Download and parse the package insert PDF to extract warnings, contraindications, and DDI information (DG001 — Blocking)
5. **Query DrugBank for MOA** — Once DrugBank ID is confirmed, retrieve mechanism of action, pharmacodynamics, and toxicity data (DG002)
6. **Re-generate evidence pack** — After resolving the above gaps, regenerate the evidence pack and re-run this evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

